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Abstract
We urgently need new therapies to improve
outcomes after cardiac arrest. Initial studies typically
target surrogate endpoints, and these studies help to
inform subsequent larger trials that are powered to
measure more patient-orientated clinical outcomes
such as survival. The competing risk of death and
premature assessment of neurological prognosis pose
significant challenges to measuring these surrogate
endpoints after cardiac arrest.
We urgently need new therapies to improve survival
with good neurological outcomes after cardiac arrest [1].
Cardiac arrest is a major global health problem, with ap-
proximately 424,000 patients experiencing an out-of-
hospital cardiac arrest each year in the USA [2]. Overall,
survival rates appear to have increased marginally over
time, but the majority of these patients will still die be-
fore hospital discharge [3]. Initial studies of new treat-
ments typically target surrogate endpoints rather than
survival; for example, reducing persistent precipitating
pathology, organ dysfunction, and markers of secondary
neurological injury [4]. Interventions that can be shown
to modify rates of these surrogate endpoints can then be
studied in larger, adequately powered trials targeting
more meaningful clinical outcomes.
In this issue of Critical Care, Donnino and colleagues
present the results of a randomized controlled trial tar-
geting one such surrogate endpoint, the reversal of
shock after cardiac arrest [1]. Specifically, they tested
whether corticosteroids—in doses similar to those used
in sepsis trials—could shorten duration of vasopressor
* Correspondence: victoria.mccredie@sunnybrook.ca
1Department of Critical Care Medicine, Sunnybrook Health Sciences Centre,
2075 Bayview Avenue, Room D108, Toronto, ON M4N 3M5, Canada
2Interdepartmental Division of Critical Care Medicine, University of Toronto,
Toronto, Ontario, Canada
Full list of author information is available at the end of the article
administration [5]. The trial addresses an important
clinical question, and the investigators conclude that
hydrocortisone does not decrease time to shock rever-
sal in post-cardiac arrest patients. Most readers will in-
terpret these results as evidence that the biological
signal—as measured by the surrogate endpoint of shock
reversal—is insufficient to justify routine use of steroids
in these patients.
However, some experts may offer other potential inter-
pretations for the apparent lack of a biological effect, in-
cluding timing of medication initiation or inclusion of
patients without adrenal insufficiency. Another possible
explanation is that many patients died before they could
achieve shock reversal, rendering this surrogate endpoint
unable to discriminate between responders and non-
responders. Indeed, more than two-thirds (34/50) of pa-
tients died before hospital discharge, and it is unclear how
many died before shock reversal [1]. The researchers used
appropriate analytical techniques to account for this
competing risk, but even the most sophisticated ana-
lyses cannot detect a change in a surrogate endpoint
when most patients die before they can experience it.
Using a surrogate endpoint becomes even more prob-
lematic when it does not actually sit on the causal path-
way. Ideally, a surrogate endpoint should have a clear
relationship as an intermediate event occurring between
the exposure of interest and the more meaningful clin-
ical outcome [6], in this case death. However, only one
patient in each group died due to refractory shock. Simi-
lar to most cardiac arrest trials, the majority of deaths
(68 %; 23/34) occurred after a decision to withdraw life-
sustaining therapy—classified as a ‘primary neurological
withdrawal of care’. Decisions to limit life support treat-
ments after cardiac arrest are usually based on predic-
tions of neurological prognosis, and may have little to
do with ongoing need for vasopressor support [7, 8].
This further obfuscates the interpretation of shock rever-
sal as a surrogate endpoint.
Current evidence-based guidelines now recommend
delaying neurological prognostication for at least 72 h
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after return of spontaneous circulation owing to the in-
accuracy of clinical examinations performed before this
time point [9]. As a consequence, any clinical trial test-
ing post-resuscitation interventions—including future
trials testing effects on surrogate endpoints—will need
to consider ways of ensuring that neurological prognos-
tication is appropriately delayed and that decisions to
withdraw life-sustaining therapy are not based solely on
subjective determinations. This type of approach was
successfully implemented in the Targeted Temperature
Management trial, which serves as a model for future
trials of post-arrest interventions [10]. To avoid the
competing risk between surrogate endpoints and deaths
related to estimates of poor neurological prognosis, future
trials could consider restricting the time frame for
measuring surrogate endpoints to earlier than 72 h.
Alternatively, trialists could choose surrogate endpoints
that clearly lie on the causal pathway between the ex-
posure of interest and subsequent decisions to with-
draw life-sustaining therapy, which is the usual mode of
death after cardiac arrest. These approaches would
introduce additional design challenges, but could improve
the interpretability of surrogate endpoints in future
cardiac arrest trials.
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